Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Other Non-Current Liabilities (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Other Non-Current Liabilities for 15 consecutive years, with $21.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 17.06% to $21.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $21.9 million, a 17.06% increase, with the full-year FY2024 number at $18.2 million, up 49.39% from a year prior.
  • Other Non-Current Liabilities was $21.9 million for Q3 2025 at Usana Health Sciences, down from $22.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $22.7 million in Q2 2025 to a low of $10.7 million in Q2 2024.
  • A 5-year average of $16.0 million and a median of $15.1 million in 2021 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: fell 29.95% in 2024, then soared 112.73% in 2025.
  • Usana Health Sciences' Other Non-Current Liabilities stood at $14.1 million in 2021, then increased by 0.78% to $14.2 million in 2022, then decreased by 14.22% to $12.2 million in 2023, then soared by 49.39% to $18.2 million in 2024, then rose by 20.61% to $21.9 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Other Non-Current Liabilities are $21.9 million (Q3 2025), $22.7 million (Q2 2025), and $20.5 million (Q1 2025).